BR112016026814A8 - 2,2,2-trifluoroetil-tiadiazinas, intermediário, seu uso e seu processo de preparação, e composição farmacêutica - Google Patents
2,2,2-trifluoroetil-tiadiazinas, intermediário, seu uso e seu processo de preparação, e composição farmacêuticaInfo
- Publication number
- BR112016026814A8 BR112016026814A8 BR112016026814A BR112016026814A BR112016026814A8 BR 112016026814 A8 BR112016026814 A8 BR 112016026814A8 BR 112016026814 A BR112016026814 A BR 112016026814A BR 112016026814 A BR112016026814 A BR 112016026814A BR 112016026814 A8 BR112016026814 A8 BR 112016026814A8
- Authority
- BR
- Brazil
- Prior art keywords
- thiadiazines
- trifluoroethyl
- pharmaceutical composition
- preparation process
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
2,2,2-trifluoroetil-tiadiazinas, intermediário, seu usi e seu processo de preparação, e composição farmacêutica. a presente invenção refere-se a compostos de fórmula (i) i, tendo atividade inibitória de bace1, sua fabricação, composições farmacêuticas que os contêm e seu uso como substâncias terapeuticamente ativas. os compostos ativos da presente invenção são úteis no tratamento terapêutico e/ou profilático de, por exemplo, doença de alzheimer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14181123 | 2014-08-15 | ||
PCT/EP2015/068506 WO2016023927A1 (en) | 2014-08-15 | 2015-08-12 | 2,2,2-trifluoroethyl-thiadiazines |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112016026814A2 BR112016026814A2 (pt) | 2017-08-15 |
BR112016026814A8 true BR112016026814A8 (pt) | 2021-07-20 |
Family
ID=51302940
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016026814A BR112016026814A8 (pt) | 2014-08-15 | 2015-08-12 | 2,2,2-trifluoroetil-tiadiazinas, intermediário, seu uso e seu processo de preparação, e composição farmacêutica |
Country Status (10)
Country | Link |
---|---|
US (1) | US9896438B2 (pt) |
EP (1) | EP3180330B1 (pt) |
JP (1) | JP6543697B2 (pt) |
KR (1) | KR20170043581A (pt) |
CN (1) | CN106459006B (pt) |
BR (1) | BR112016026814A8 (pt) |
CA (1) | CA2952160A1 (pt) |
MX (1) | MX2016016061A (pt) |
RU (1) | RU2692102C2 (pt) |
WO (1) | WO2016023927A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109180672A (zh) * | 2018-09-29 | 2019-01-11 | 广东东阳光药业有限公司 | 亚氨基噻二嗪二氧化物衍生物及其用途 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19500558A1 (de) * | 1995-01-11 | 1996-07-18 | Merck Patent Gmbh | 3-Alkoxycarbonyl-thiadiazinone |
UA108363C2 (uk) * | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
WO2011044184A1 (en) * | 2009-10-08 | 2011-04-14 | Schering Corporation | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
WO2014150340A1 (en) * | 2013-03-15 | 2014-09-25 | Merck Sharp & Dohme Corp. | S-imino-s-oxo iminothiadiazine compounds as bace inhibitors, compositions, and their use |
EP2968357B1 (en) * | 2013-03-15 | 2018-07-04 | Merck Sharp & Dohme Corp. | S-imino-s-oxo iminothiazine compounds as bace inhibitors, compositions, and their use |
RU2016128365A (ru) * | 2013-12-20 | 2018-01-25 | Ф. Хоффманн-Ля Рош Аг | 5-арил-1-имино-1-оксо-[1,2,4]тиадиазины |
-
2015
- 2015-08-12 MX MX2016016061A patent/MX2016016061A/es active IP Right Grant
- 2015-08-12 CA CA2952160A patent/CA2952160A1/en not_active Abandoned
- 2015-08-12 CN CN201580032183.8A patent/CN106459006B/zh not_active Expired - Fee Related
- 2015-08-12 WO PCT/EP2015/068506 patent/WO2016023927A1/en active Application Filing
- 2015-08-12 JP JP2017506993A patent/JP6543697B2/ja not_active Expired - Fee Related
- 2015-08-12 KR KR1020177006946A patent/KR20170043581A/ko not_active Application Discontinuation
- 2015-08-12 RU RU2017107495A patent/RU2692102C2/ru active
- 2015-08-12 US US15/502,044 patent/US9896438B2/en active Active
- 2015-08-12 EP EP15748252.2A patent/EP3180330B1/en active Active
- 2015-08-12 BR BR112016026814A patent/BR112016026814A8/pt active Search and Examination
Also Published As
Publication number | Publication date |
---|---|
US9896438B2 (en) | 2018-02-20 |
JP6543697B2 (ja) | 2019-07-10 |
CA2952160A1 (en) | 2016-02-18 |
EP3180330B1 (en) | 2021-03-03 |
WO2016023927A1 (en) | 2016-02-18 |
MX2016016061A (es) | 2017-03-10 |
RU2017107495A3 (pt) | 2019-02-25 |
US20170226091A1 (en) | 2017-08-10 |
RU2692102C2 (ru) | 2019-06-21 |
JP2017524006A (ja) | 2017-08-24 |
EP3180330A1 (en) | 2017-06-21 |
CN106459006B (zh) | 2020-02-11 |
BR112016026814A2 (pt) | 2017-08-15 |
RU2017107495A (ru) | 2018-09-17 |
CN106459006A (zh) | 2017-02-22 |
KR20170043581A (ko) | 2017-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015016315A2 (pt) | fluoro-[1,3]oxazinas como inibidores de bace1 | |
BR112013031098A2 (pt) | halogeno-alquil-1,3 oxazinas como inibidores de bace1 e/ou bace2 | |
BR112018076534A2 (pt) | compostos heterocíclicos como imunomoduladores | |
BR112014015630A8 (pt) | fluorometil-5,6-di-hidro-4h-[1,3]oxazinas, seus usos, e composição farmacêutica | |
BR112015019412A2 (pt) | inibidores de bace1 | |
BR112015021888A8 (pt) | inibidores de dna-pk, seus usos e composição farmacêutica | |
EA201391752A1 (ru) | Спиро-[1,3]-оксазины и спиро-[1,4]-оксазепины в качестве ингибиторов bace1 и/или bace2 | |
EA201391670A1 (ru) | 1,3-оксазины в качестве ингибиторов bace1 и/или bace2 | |
BR112013031510A2 (pt) | [1,3]oxazinas | |
BR112013019955A2 (pt) | n-[3-(5-amino-3,3a,7,7a-tetra-hidro-1h-2,4-dioxa-6-aza-inden-7-il)-fenil]-amidas como inibidores de bace1 e/ou de bace2 | |
MX2013007558A (es) | 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2). | |
MX2013007957A (es) | 1,4-oxazinas como inhibidores de los genes de enzima de segmentacion de la proteina precursora amiloide del sitio beta 1 y/o (bace1 y/o bace2). | |
BR112013021798A2 (pt) | 1,4 tiazepinaas/sulfonas como inibidores de bace1 e/ou bace2 | |
BR112019024830A2 (pt) | inibidores de bcl6 derivados de benzimidazolona | |
BR112014028813A2 (pt) | 5-amino[1,4]tiazinas como inibidores bace1 | |
BR112014006763A2 (pt) | n-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexa-hidro-ciclopenta[e][1,3]oxazin-4-il)-fenil)-amidas como inibidores de bace1 | |
EA201590066A1 (ru) | Дифторгексагидроциклопентаоксазинилы и дифторгексагидробензоксазинилы в качестве ингибиторов бета-секретазы 1 | |
BR112017022757A2 (pt) | derivados do pirazol úteis como inibidores da proteína ativadora da 5-lipoxigenase (flap) | |
BR112017015474A2 (pt) | inibidores de bace1 | |
BR112016007430A2 (pt) | 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas | |
BR112016026814A8 (pt) | 2,2,2-trifluoroetil-tiadiazinas, intermediário, seu uso e seu processo de preparação, e composição farmacêutica | |
BR112019000603A2 (pt) | composto, composição farmacêutica, método para o tratamento de doenças e uso do composto | |
EA201400492A1 (ru) | Фармацевтические композиции, содержащие комбинацию основания абакавира и ламивудина |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B11D | Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time |